Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Anavex Life Sciences Corp. (AVXL)

12.38   -0.27 (-2.13%) 01-21 17:31
Open: 12.5 Pre. Close: 12.65
High: 13 Low: 12.29
Volume: 1,185,495 Market Cap: 941M
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 13.016 - 13.097 13.097 - 13.154
Low: 12.103 - 12.201 12.201 - 12.271
Close: 12.251 - 12.395 12.395 - 12.496

Technical analysis

as of: 2022-01-21 4:24:57 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 19.80     One year: 23.16
Support: Support1: 12.29    Support2: 10.23
Resistance: Resistance1: 16.95    Resistance2: 19.83
Pivot: 14.89
Moving Average: MA(5): 13.24     MA(20): 15.73
MA(100): 18.26     MA(250): 16.87
MACD: MACD(12,26): -1.48     Signal(9): -1.19
Stochastic oscillator: %K(14,3): 3.44     %D(3): 4.90
RSI: RSI(14): 27.23
52-week: High: 31.50  Low: 6.12  Change(%): 105.3
Average Vol(K): 3-Month: 956  10-Days: 1036

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.
AVXL has closed above bottom band by 8.9%. Bollinger Bands are 51.8% wider than normal. The large width of the bands suggest high volatility as compared to Anavex Life Sciences Corp.'s normal range. The bands have been in this wide range for 9 bars. This is a sign that the current trend might continue.

Headline News

Thu, 06 Jan 2022
Anavex Life Sciences Promotes Walter E Kaufmann, MD to - GlobeNewswire

Mon, 03 Jan 2022
When Can We Expect A Profit From Anavex Life Sciences Corp. (NASDAQ:AVXL)? - Nasdaq

Sun, 19 Dec 2021
Zacks: Brokerages Anticipate Anavex Life Sciences Corp. (NASDAQ:AVXL) Will Post Earnings of -$0.16 Per Share - MarketBeat

Tue, 14 Dec 2021
Anavex Life Sciences to Present at 40th Annual JP Morgan - GlobeNewswire

Wed, 24 Nov 2021
Anavex Life Sciences Provides Business Update and Reports Fiscal 2021 Year End Financial Results - GlobeNewswire

Mon, 01 Nov 2021
Anavex Life Sciences Corp (AVXL) has fallen 6.88% Monday In Premarket Trading - InvestorsObserver

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Underperform Price to Earnings: Underperform
Return on Equity: Underperform Debt to Equity: Neutral
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 76
Shares Float (M) 74
% Held by Insiders 3.20
% Held by Institutions 28.13
Shares Short (K) 4,500
Shares Short P. Month (K) 4,810

Stock Financials

EPS -0.540
EPS Est This Year
EPS Est Next Year
Book Value (p.s.) 1.990
Profit Margin
Operating Margin
Return on Assets (ttm) -23.9
Return on Equity (ttm) -42.6
Qtrly Rev. Growth
Gross Profit (p.s.)
Sales Per Share
EBITDA (p.s.)
Qtrly Earnings Growth
Operating Cash Flow (M) -30
Levered Free Cash Flow (M) -16

Stock Valuations

PE Ratio -22.93
PEG Ratio
Price to Book value 6.22
Price to Sales
Price to Cash Flow

Stock Dividends

Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2020 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.